Advertisement
Advertisement
U.S. markets open in 5 hours 53 minutes
Advertisement
Advertisement
Advertisement
Advertisement

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.0600+0.0400 (+3.92%)
At close: 04:00PM EDT
1.0700 +0.01 (+0.94%)
After hours: 05:31PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close1.0200
Open1.0500
Bid0.0000 x 800
Ask0.0000 x 1400
Day's Range1.0200 - 1.0700
52 Week Range0.9000 - 11.1800
Volume280,554
Avg. Volume421,085
Market Cap55.916M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)-2.1010
Earnings DateMay 25, 2022 - May 30, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RDHL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Redhill Biopharma Ltd.
    Daily – Vickers Top Buyers & Sellers for 05/16/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • American City Business Journals

    Raleigh drugmaker pursuing Covid treatment raising $15M to fund acquisitions

    Additionally, the company agreed to issue unregistered private warrants to the investor to purchase up to more than 13 million shares at $1.48 a share in a concurrent private placement, according to a filing with the U.S. Securities and Exchange Commission. RedHill's stock fell more than 30 percent Monday after the company disclosed the offering prior to markets opening. The offering follows the company signing a licensing deal with the South Korean corporation Kubo Co. Ltd for the exclusive rights to commercialize RedHill's investigational Covid-19 treatment called opaganib.

  • PR Newswire

    RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor

    RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement with a single leading healthcare investor for the purchase and sale of 10,563,380 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing ten (10) ordinary shares, at a purchase price of $1.42 per ADS (or ADS equivalent), in a registered direct offering. RedHill has also agreed to issue

  • Insider Monkey

    Cathie Wood’s Latest Portfolio: 10 New Stock Picks in 2022

    In this article we will discuss some new stock picks of Cathie Wood’s hedge fund. You can skip this part and go directly to see the top 5 New Stock Picks of Cathie Wood in 2022. Despite huge criticism and losses, Cathie Wood’s hedge fund ARK Investment continues to attract investors amid promises of future […]

Advertisement
Advertisement